Replies to post #186886 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

For those that haven't seen today's poster:

https://learningcenter.ehaweb.org/eha/2017/22nd/180680/roberta.napolitano.kevetrin.preclinical.study.of.a.new.compound.in.acute.html

KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ACUTE MYELOID LEUKEMIA

Conclusion
Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.

However, I'm more interested in seeing trial results this year from the kevetrin ph2 Ovarian Cancer trial since it will answer a few important questions.

https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=1&flds=abcefgps&submit_fld_opt=









In Reply to 'Jhawker'
I am very excited about the poster that was presented today. AML is a very deadly and almost incurable blood disease.